The role of sphingosine-1-phosphate in bone remodeling and osteoporosis

Abstract

Osteoporosis is a systemic bone disease that affects more than 200 million people worldwide and is caused by the disruption of the equilibrium between osteoclastic bone resorption and osteoblastic bone formation. Sphingosine-1-phosphate (S1P) is a natural, bioactive sphingolipid that has been shown to play a major role in cardiovascular and immunological pathologies by regulating biological and cellular processes, including migration, differentiation, proliferation and survival. Recent studies also suggest a central role for S1P in bone diseases, including osteoporosis; however, the effects of S1P, particularly in bone metabolism, remain to be further elucidated. In this review, we summarize the available literature on the role of S1P in bone metabolism with a focus on osteoporosis. On the cellular level, S1P acts as an osteoclast-osteoblast coupling factor to promote osteoblast proliferation and bone formation. Moreover, the recruitment of osteoclast precursors to resorption sites is regulated by the interplay of S1P gradients and S1P receptor expression. From a clinical perspective, increasing evidence suggests that systemically elevated S1P blood levels may serve as an independent risk factor for osteoporosis-related fractures. Taken together, S1P signaling is a potential therapeutic target and may serve as a novel biomarker in patients with systemic bone disease.

References

[1] Harvey N, Dennison E, Cooper C. Osteoporosis: impact on health and economics. Nat. Rev. Rheumatol., 2010, 6: 99-105

[2] Sözen T, Özışık L, Başaran N. An overview and management of osteoporosis. Eur. J. Rheumatol., 2017, 4: 46-56

[3] Johnell O, Kanis J. Epidemiology of osteoporotic fractures. Osteoporos. Int., 2005, 16: S3-S7

[4] Borgström F et al. Costs and quality of life associated with osteoporosis-related fractures in Sweden. Osteoporos. Int., 2006, 17: 637-650

[5] Ioannidis G et al. Relation between fractures and mortality: results from the Canadian Multicentre Osteoporosis Study. CMAJ, 2009, 181: 265-271

[6] Hauge EM, Qvesel D, Eriksen EF, Mosekilde L, Melsen F. Cancellous bone remodeling occurs in specialized compartments lined by cells expressing osteoblastic markers. J. Bone Min. Res., 2001, 16: 1575-1582

[7] Florencio-Silva R, Sasso GRdS, Sasso-Cerri E, Simões MJ, Cerri PS. Biology of bone tissue: structure, function, and factors that influence bone cells. Biomed. Res. Int., 2015, 2015: 421746

[8] Daum G, Grabski A, Reidy MA. Sphingosine 1-phosphate: a regulator of arterial lesions. Arterioscler Thromb. Vasc. Biol., 2009, 29: 1439-1443

[9] Pyne NJ, Pyne S. Sphingosine 1-phosphate and cancer. Nat. Rev. Cancer, 2010, 10: 489-503

[10] Ng ML, Wadham C, Sukocheva OA. The role of sphingolipid signalling in diabetes‑associated pathologies (Review). Int J. Mol. Med., 2017, 39: 243-252

[11] Sartawi Z, Schipani E, Ryan KB, Waeber C. Sphingosine 1-phosphate (S1P) signalling: Role in bone biology and potential therapeutic target for bone repair. Pharm. Res., 2017, 125: 232-245

[12] Cohan S, Lucassen E, Smoot K, Brink J, Chen C. Sphingosine-1-phosphate: its pharmacological regulation and the treatment of multiple sclerosis: a review article. Biomedicines, 2020, 8: 227

[13] Spiegel S, Milstien S. Sphingosine-1-phosphate: an enigmatic signalling lipid. Nat. Rev. Mol. Cell Biol., 2003, 4: 397-407

[14] Cuvillier O et al. Suppression of ceramide-mediated programmed cell death by sphingosine-1-phosphate. Nature, 1996, 381: 800-803

[15] Nagahashi M et al. Sphingosine-1-phosphate transporters as targets for cancer therapy. Biomed. Res. Int., 2014, 2014: 651727

[16] Im DS et al. Characterization of a novel sphingosine 1-phosphate receptor, Edg-8. J. Biol. Chem., 2000, 275: 14281-14286

[17] Kumar A, Saba JD. Lyase to live by: sphingosine phosphate lyase as a therapeutic target. Expert Opin. Ther. Targets, 2009, 13: 1013-1025

[18] Brindley DN, Pilquil C. Lipid phosphate phosphatases and signaling. J. Lipid Res., 2009, 50: S225-S230

[19] Murata N et al. Interaction of sphingosine 1-phosphate with plasma components, including lipoproteins, regulates the lipid receptor-mediated actions. Biochem. J., 2000, 352: 809-815

[20] Sattler K, Levkau B. Sphingosine-1-phosphate as a mediator of high-density lipoprotein effects in cardiovascular protection. Cardiovasc. Res., 2009, 82: 201-211

[21] Ito K et al. Lack of sphingosine 1-phosphate-degrading enzymes in erythrocytes. Biochem. Biophys. Res. Commun., 2007, 357: 212-217

[22] Golan K, Kollet O, Lapidot T. Dynamic cross talk between S1P and CXCL12 regulates hematopoietic stem cells migration, development and bone remodeling. Pharm. (Basel), 2013, 6: 1145-1169

[23] Proia RL, Hla T. Emerging biology of sphingosine-1-phosphate: its role in pathogenesis and therapy. J. Clin. Invest., 2015, 125: 1379-1387

[24] Meyer zu Heringdorf D, Jakobs KH. Lysophospholipid receptors: signalling, pharmacology and regulation by lysophospholipid metabolism. Biochim. Biophys. Acta, 2007, 1768: 923-940

[25] Keller J et al. Calcitonin controls bone formation by inhibiting the release of sphingosine 1-phosphate from osteoclasts. Nat. Commun., 2014, 5

[26] Zhang L et al. Sphingosine-1-phosphate (S1P) receptors: Promising drug targets for treating bone-related diseases. J. Cell Mol. Med., 2020, 24: 4389-4401

[27] Brar KS. Prevalent and emerging therapies for osteoporosis. Med J. Armed Forces India, 2010, 66: 249-254

[28] Ratajczak MZ et al. Novel insight into stem cell mobilization-plasma sphingosine-1-phosphate is a major chemoattractant that directs the egress of hematopoietic stem progenitor cells from the bone marrow and its level in peripheral blood increases during mobilization due to activation of complement cascade/membrane attack complex. Leukemia, 2010, 24: 976-985

[29] Ishii M et al. Sphingosine-1-phosphate mobilizes osteoclast precursors and regulates bone homeostasis. Nature, 2009, 458: 524-528

[30] Ishii M, Kikuta J, Shimazu Y, Meier-Schellersheim M, Germain RN. Chemorepulsion by blood S1P regulates osteoclast precursor mobilization and bone remodeling in vivo. J. Exp. Med., 2010, 207: 2793-2798

[31] Kikuta J et al. Sphingosine-1-phosphate-mediated osteoclast precursor monocyte migration is a critical point of control in antibone-resorptive action of active vitamin D. Proc. Natl Acad. Sci. USA, 2013, 110: 7009-7013

[32] Ishii T, Shimazu Y, Nishiyama I, Kikuta J, Ishii M. The role of sphingosine 1-phosphate in migration of osteoclast precursors; an application of intravital two-photon microscopy. Mol. Cells, 2011, 31: 399-403

[33] Leucht P et al. CXCR4 antagonism attenuates load-induced periosteal bone formation in mice. J. Orthop. Res., 2013, 31: 1828-1838

[34] Kennedy OD et al. Activation of resorption in fatigue-loaded bone involves both apoptosis and active pro-osteoclastogenic signaling by distinct osteocyte populations. Bone, 2012, 50: 1115-1122

[35] Tang Y et al. TGF-beta1-induced migration of bone mesenchymal stem cells couples bone resorption with formation. Nat. Med., 2009, 15: 757-765

[36] Schaller S et al. The chloride channel inhibitor NS3736 prevents bone resorption in ovariectomized rats without changing bone formation. J. Bone Min. Res., 2004, 19: 1144-1153

[37] Ryu J et al. Sphingosine 1-phosphate as a regulator of osteoclast differentiation and osteoclast-osteoblast coupling. EMBO J., 2006, 25: 5840-5851

[38] Matsuzaki E et al. Sphingosine-1-phosphate promotes the nuclear translocation of β-catenin and thereby induces osteoprotegerin gene expression in osteoblast-like cell lines. Bone, 2013, 55: 315-324

[39] Lotinun S et al. Osteoclast-specific cathepsin K deletion stimulates S1P-dependent bone formation. J. Clin. Invest., 2013, 123: 666-681

[40] Weske S et al. Targeting sphingosine-1-phosphate lyase as an anabolic therapy for bone loss. Nat. Med., 2018, 24: 667-678

[41] Weske S et al. Agonist-induced activation of the S1P receptor 2 constitutes a novel osteoanabolic therapy for the treatment of osteoporosis in mice. Bone, 2019, 125: 1-7

[42] Heckt T, Brylka LJ, Neven M, Amling M, Schinke T. Deficiency of sphingosine-1-phosphate receptor 3 does not affect the skeletal phenotype of mice lacking sphingosine-1-phosphate lyase. PLoS ONE, 2019, 14: e0219734

[43] Brizuela L et al. Osteoblast-derived sphingosine 1-phosphate to induce proliferation and confer resistance to therapeutics to bone metastasis-derived prostate cancer cells. Mol. Oncol., 2014, 8: 1181-1195

[44] Quint P et al. Sphingosine 1-phosphate (S1P) receptors 1 and 2 coordinately induce mesenchymal cell migration through S1P activation of complementary kinase pathways. J. Biol. Chem., 2013, 288: 5398-5406

[45] Pederson L, Ruan M, Westendorf JJ, Khosla S, Oursler MJ. Regulation of bone formation by osteoclasts involves Wnt/BMP signaling and the chemokine sphingosine-1-phosphate. Proc. Natl Acad. Sci. USA, 2008, 105: 20764-20769

[46] Sanchez-Fernandez MA, Gallois A, Riedl T, Jurdic P, Hoflack B. Osteoclasts control osteoblast chemotaxis via PDGF-BB/PDGF receptor beta signaling. PLoS ONE, 2008, 3: e3537

[47] Roelofsen T et al. Sphingosine-1-phosphate acts as a developmental stage specific inhibitor of platelet-derived growth factor-induced chemotaxis of osteoblasts. J. Cell Biochem., 2008, 105: 1128-1138

[48] Grey A et al. The phospholipids sphingosine-1-phosphate and lysophosphatidic acid prevent apoptosis in osteoblastic cells via a signaling pathway involving Gi proteins and phosphatidylinositol-3 kinase. Endocrinology, 2002, 143: 4755-4763

[49] Dziak R et al. Effects of sphingosine-1-phosphate and lysophosphatidic acid on human osteoblastic cells. Prostaglandins Leukot. Ess. Fat. Acids, 2003, 68: 239-249

[50] Grey A et al. Osteoblastic cells express phospholipid receptors and phosphatases and proliferate in response to sphingosine-1-phosphate. Calcif. Tissue Int., 2004, 74: 542-550

[51] Ji F et al. K6PC-5, a novel sphingosine kinase 1 (SphK1) activator, alleviates dexamethasone-induced damages to osteoblasts through activating SphK1-Akt signaling. Biochem. Biophys. Res. Commun., 2015, 458: 568-575

[52] Tantikanlayaporn D et al. Sphingosine-1-phosphate modulates the effect of estrogen in human osteoblasts. JBMR, 2018, 2: 217-226

[53] Xie H et al. PDGF-BB secreted by preosteoclasts induces angiogenesis during coupling with osteogenesis. Nat. Med., 2014, 20: 1270-1278

[54] Kanis J, Johnell O, Odén A, Johansson H, McCloskey E. FRAX™ and the assessment of fracture probability in men and women from the UK. Osteoporos. Int., 2008, 19: 385-397

[55] Greenblatt MB, Tsai JN, Wein MN. Bone turnover markers in the diagnosis and monitoring of metabolic bone disease. Clin. Chem., 2017, 63: 464-474

[56] Eastell R et al. Evaluation of bone turnover in type I osteoporosis using biochemical markers specific for both bone formation and bone resorption. Osteoporos. Int., 1993, 3: 255-260

[57] Bae SJ et al. The circulating sphingosine-1-phosphate level predicts incident fracture in postmenopausal women: a 3.5-year follow-up observation study. Osteoporos. Int., 2016, 27: 2533-2541

[58] Kim B-J et al. Plasma sphingosine 1-phosphate levels and the risk of vertebral fracture in postmenopausal women. J. Clin. Endocrinol. Metab., 2012, 97: 3807-3814

[59] Ardawi MM et al. High plasma sphingosine 1-phosphate levels predict osteoporotic fractures in postmenopausal women: The Center of Excellence for Osteoporosis Research Study. J. Bone Metab., 2018, 25: 87-98

[60] Lee SH et al. High circulating sphingosine 1-phosphate is a risk factor for osteoporotic fracture independent of fracture risk assessment tool. Calcif. Tissue Int., 2020, 107: 362-370

[61] Song HE et al. Association of circulating levels of total and protein-bound sphingosine 1-phosphate with osteoporotic fracture. J. Investig. Med., 2020, 68: 1295-1299

[62] Lee SH et al. Higher circulating sphingosine 1-phosphate levels are associated with lower bone mineral density and higher bone resorption marker in humans. J. Clin. Endocrinol. Metab., 2012, 97: E1421-E1428

[63] Lee SH et al. Associations of circulating levels of sphingosine 1-phosphate with the trabecular bone score and bone mineral density in postmenopausal women. J. Clin. Densitom., 2021, 24: 414-421

[64] Silva BC et al. Trabecular bone score: a noninvasive analytical method based upon the DXA image. J. Bone Min. Res., 2014, 29: 518-530

[65] Ahn SH et al. Association of bone marrow sphingosine 1-phosphate levels with osteoporotic hip fractures. J. Bone Metab., 2013, 20: 61-65

[66] Kim BJ et al. The effect of sphingosine-1-phosphate on bone metabolism in humans depends on its plasma/bone marrow gradient. J. Endocrinol. Invest., 2016, 39: 297-303

[67] Rivera J, Proia RL, Olivera A. The alliance of sphingosine-1-phosphate and its receptors in immunity. Nat. Rev. Immunol., 2008, 8: 753-763

[68] Miyazaki Y et al. Fingolimod suppresses bone resorption in female patients with multiple sclerosis. J. Neuroimmunol., 2016, 298: 24-31

[69] Kenkre JS, Bassett J. The bone remodelling cycle. Ann. Clin. Biochem., 2018, 55: 308-327

[70] Smith JK. Osteoclasts and microgravity. Life (Basel), 2020, 10: 207

[71] Lamy O, Stoll D, Aubry-Rozier B, Rodriguez EG. Stopping Denosumab. Curr. Osteoporos. Rep., 2019, 17: 8-15

[72] Fabre S, Funck-Brentano T, Cohen-Solal M. Anti-Sclerostin antibodies in osteoporosis and other bone diseases. J. Clin. Med., 2020, 9: 3439

[73] Kappos L et al. Oral Fingolimod (FTY720) for relapsing multiple sclerosis. N. Engl. J. Med., 2006, 355: 1124-1140

[74] Sanna MG et al. Sphingosine 1-phosphate (S1P) receptor subtypes S1P1 and S1P3, respectively, regulate lymphocyte recirculation and heart rate. J. Biol. Chem., 2004, 279: 13839-13848

[75] Lynch, K. R. et al. Inhibitors of spinster homolog 2 (SPNS2) for use in therapy. US patent (2020). https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2020154431. (Accessed on 15 Aug 2021).

[76] Heilmann A et al. Systemic treatment with the sphingosine-1-phosphate analog FTY720 does not improve fracture healing in mice. J. Orthop. Res., 2013, 31: 1845-1850

[77] Doschak MR, Kucharski CM, Wright JE, Zernicke RF, Uludağ H. Improved bone delivery of osteoprotegerin by bisphosphonate conjugation in a rat model of osteoarthritis. Mol. Pharm., 2009, 6: 634-640

[78] Park CH et al. Impact on bisphosphonate persistence and compliance: daily postprandial administration. J. Bone Metab., 2019, 26: 39-44

[79] Chen JH et al. Bispecific antibody binding To RANKL and osteonectin with enhanced localization to the bone. Mol. Pharm., 2017, 14: 4113-4120

[80] Shahifar N et al. Bone turnover markers and sphingosine-1-phosphate levels among the Chinese Community in Selangor, Malaysia and its correlation with bone density. MJMHS, 2020, 16: 46-51

Funding

Else-Kröner-Fresenius-Stiftung (EKFS 2017_A22)